Paroxetine long-term safety and efficacy in panic disorder and prevention of relapse: A double-blind study

Judge, R.; Burnham, Daniel B.; Steiner, Martin; Gergel, I.; Oakes, Rosemary; Bailer, Dennis; Wheadon, David E.

doi:10.1016/0924-9338(96)89093-6

“…The results of our study showed that paroxetine is highly efficacious in the short-term and intermediate-term treatment of PD and PDA, and this is consistent with the results of numerous efficacy studies [21-23]. The high efficacy rate of paroxetine pharmacotherapy also closely reflects the high response rates seen with Cognitive Behavioral Therapy [3].…”

Section: Discussionsupporting

confidence: 88%

Three year naturalistic outcome study of panic disorder patients treated with paroxetine

Dannon

¹

,

Iancu

²

,

Cohen

³

et al. 2004

View full text Add to dashboard Cite

show abstract

“…One double-blind trial compared paroxetine plus cognitive therapy to placebo plus cognitive therapy [II] [100]. Paroxetine reduces the number of panic attacks and prevents relapse for up to 9 months [II] [99,102]. Paroxetine reduces the number of panic attacks and prevents relapse for up to 9 months [II] [99,102].…”

Section: Specific Ssrismentioning

confidence: 99%

“…Significantly, more patients in the paroxetine group achieved a 50% reduction in panic frequency. Paroxetine reduces the number of panic attacks and prevents relapse for up to 9 months [II] [99, 102]. It has a similar side-effect profile to other SSRIs, most notably nausea and sweating, and there is a problem with discontinuation.…”

Section: Beneficial Interventionsmentioning

confidence: 99%

Australian and New Zealand Clinical Practice Guidelines for the Treatment of Panic Disorder and Agoraphobia

2003

Aust N Z J Psychiatry

View full text Add to dashboard Cite

Education for the patient and significant others covering: (i) the nature and course of panic disorder and agoraphobia; (ii) an explanation of the psychopathology of anxiety, panic and agoraphobia; (iii) rationale for the treatment, likelihood of a positive response, and expected time frame. Cognitive behaviour therapy (CBT) is more effective and more cost-effective than medication. Tricyclic antidepressants (TCAs) and serotonin selective reuptake inhibitors are equal in efficacy and both are to be preferred to benzodiazepines. Treatment choice depends on the skill of the clinician and the patient's circumstances. Drug treatment should be complemented by behaviour therapy. If the response to an adequate trial of a first-line treatment is poor, another evidence-based treatment should be used. A second opinion can be useful. The presence of severe agoraphobia is a negative prognostic indicator, whereas comorbid depression, if properly treated, has no consistent effect on outcome.

show abstract

“…Significantly, more patients in the paroxetine group achieved a 50% reduction in panic frequency. Paroxetine reduces the number of panic attacks and prevents relapse for up to 9 months [II][99,102]. It has a similar side‐effect profile to other SSRIs, most notably nausea and sweating, and there is a problem with discontinuation.…”

mentioning

confidence: 99%

Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia

2003

Aust N Z J Psychiatry

View full text Add to dashboard Cite

Education for the patient and significant others covering: (i) the nature and course of panic disorder and agoraphobia; (ii) an explanation of the psychopathology of anxiety, panic and agoraphobia; (iii) rationale for the treatment, likelihood of a positive response, and expected time frame. Cognitive behaviour therapy (CBT) is more effective and more cost-effective than medication. Tricyclic antidepressants (TCAs) and serotonin selective reuptake inhibitors are equal in efficacy and both are to be preferred to benzodiazepines. Treatment choice depends on the skill of the clinician and the patient's circumstances. Drug treatment should be complemented by behaviour therapy. If the response to an adequate trial of a first-line treatment is poor, another evidence-based treatment should be used. A second opinion can be useful. The presence of severe agoraphobia is a negative prognostic indicator, whereas comorbid depression, if properly treated, has no consistent effect on outcome.

show abstract

Paroxetine long-term safety and efficacy in panic disorder and prevention of relapse: A double-blind study

Cited by 7 publications

References 0 publications

Three year naturalistic outcome study of panic disorder patients treated with paroxetine

Three year naturalistic outcome study of panic disorder patients treated with paroxetine

Australian and New Zealand Clinical Practice Guidelines for the Treatment of Panic Disorder and Agoraphobia

Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia

Contact Info

Product

Resources

About